About PetMedix
PetMedix is a company based in Babraham (United Kingdom) founded in 2017 by Thomas Weaver was acquired by Zoetis in September 2023. PetMedix has raised $47.46 million across 3 funding rounds from investors including Tencent, Zoetis and Parkwalk. The company has 44 employees as of January 31, 2022. PetMedix operates in a competitive market with competitors including Zoetis, Ceva, QBiotics, Bio-Sourcing and Hester Biosciences, among others.
- Headquarter Babraham, United Kingdom
- Employees 44 as on 31 Jan, 2022
- Founders Thomas Weaver
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Petmedix Ltd
- Date of Incorporation 05 Dec, 2017
- Jurisdiction CAMBRIDGE, CAMBRIDGESHIRE, ENGLAND
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of PetMedix
PetMedix has successfully raised a total of $47.46M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $37 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PetMedix
PetMedix has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Tencent, Zoetis and Parkwalk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech companies are invested in by Parkwalk venture capital firm.
|
Locked | Locked | Locked | |
|
Digitalis Ventures is engaged in health-focused investments.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in life sciences and deep tech.
|
Locked | Locked | Locked |
Investor details for PetMedix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PetMedix
Investment portfolio details for PetMedix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PetMedix
Detailed financials for PetMedix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Petmedix Comparisons
Peer comparison for PetMedix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PetMedix
PetMedix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zoetis, Ceva, QBiotics, Bio-Sourcing and Hester Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Animal medicines, vaccines, and diagnostics are manufactured and supplied.
|
|
| Locked | Locked | Locked |
Animal health therapeutics are developed and supplied globally by Ceva.
|
|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Biopharmaceuticals for animals are manufactured and supplied through partnerships.
|
|
| Locked | Locked | Locked |
Manufacturer of animal vaccines and healthcare products
|
Detailed competitors of PetMedix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Petmedix
Complete news archive for PetMedix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PetMedix
PetMedix was founded in 2017 and raised its 1st funding round 2 years after it was founded.
PetMedix is headquartered in Babraham, United Kingdom. It is registered at Babraham, Cambridgeshire, United Kingdom.
Thomas Weaver is the current CEO of PetMedix. They have also founded this company.
PetMedix is a funded company, having raised a total of $47.46M across 3 funding rounds to date.
As of Jan 31, 2022, the latest employee count at PetMedix is 44.
PetMedix was founded in 2017 in Babraham, United Kingdom, within the biotechnology sector focused on veterinary medicine. Monoclonal antibody therapeutics for pets are developed to address cancer, inflammation, and other conditions. The Ky9 and Felyne platforms are utilized to generate these antibodies, supporting operations in therapeutic innovation for animal health. Leadership includes co-founder Thomas Weaver as CEO.
PetMedix has 6 investors. Key investors include Tencent, Zoetis, Parkwalk, Digitalis Ventures, and Cambridge Innovation Capital.